Pharmacologic treatments for covid-19 patients

Molnupiravir vs Standard care/Placebo


Outpatients

Forest plots
(last update: 2022-11-04)

Summary of findings
(last update: 2022-11-22)

Hospitalized patients

Forest plots
(last update: 2022-09-15)

To access all information :

You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.

Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=512

Back to your research

Trial Funding Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Treatment 1 Treatment 2
ChiCTR2200056817
Zou R, Front Pharm, 2022
Full text
Commentary
Mixed

Molnupiravir

Standard care

RCT Patients with confirmed COVID-19 (mild) isolated and treated by a single center in China N=116
Some concerns
Details

Full description

ISRCTN30448031; EudraCT: 2021-005748-31
PANORAMIC
Butler C, SSRN, 2022
Full text
Commentary
Public/non profit

Molnupiravir

Standard care

RCT Outpatients with confirmed COVID-19 (mild-ambulatory) treated by multiple centers in the UK N=25783
High
Details

Full description

NCT04746183; ISRCTN27106947; EudraCT 2020-001860-2
AGILE CST-2
Khoo SH, medRxiv, 2022
Full text
Commentary
Commentary
Mixed

Molnupiravir

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 5 centers in the UK N=180
Some concerns
Details

Full description

CTRI/2021/06/033938
Kumarasamy N, CROI, 2022
Full text
Private

Molnupiravir

Standard care

RCT Outpatients with confirmed COVID-19 (mild) treated in 26 centers in India. N=1218
Some concerns
Details

Full description

CTRI/2021/07/034588
Koudinya Tippabhotla S, SSRN, 2022
Full text
Commentary
Commentary
Private

Molnupiravir

Standard care

RCT Outpatients with confirmed COVID-19 (mild) treated at 16 centers in India N=1220
Some concerns
Details

Full description

NCT04575584
MOVe-IN
Arribas J, N Engl J Med Evidence, 2021
Full text
Commentary
Commentary
Private

Molnupiravir 200mg

Placebo

RCT Patients with suspeccted or confirmed COVID-19 (mild-moderate-severe) admitted to 65 centers in Brazil, Chile, Colombia, France, Israel, Mexico, Philippines, Poland, Russia, South Africa, South Korea N=304
Some concerns
Details

Full description

NCT04575597
MOVe-OUT
Caraco Y, N Engl J Med Evidence, 2021
Full text
Commentary
Private

Molnupiravir 200

Molnupiravir 400

Molnupiravir

Placebo

RCT Outpatients with confirmed COVID-19 (asymptomatic, mild) treated by 82 centers in 14 countries N=302
Low
Details

Full description

NCT04575597
Jayk Bernal A, N Engl J Med, 2021
Full text
Commentary
Private

Molnupiravir

Placebo

RCT Outpatients with confirmed COVID-19 (mild-moderate) treated by 107 sites in 20 countries. N=1433
Low
Details

Full description

NCT04405570
Fischer W, Sci Transl Med, 2021
Full text
Full text
Commentary
Commentary
Commentary
Mixed

Molnupiravir 200

Molnupiravir 400

Molnupiravir

Placebo

RCT Outpatients with confirmed COVID-19 (mild) treated by 10 centers in the USA N=202
High
Details

Full description